AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03406039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Online CBT and MI
Description: The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
Study NCT03014531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: almond
Study NCT03014531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high-carbohydrate control food
Study NCT02995967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention
Description: The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
Study NCT02995967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin-A
Description: Intradetrusor injection of 100 units of botulinum toxin a
Study NCT05061264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal wall reconstruction
Description: The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
Study NCT02951884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration
Description: A needle is placed into the knee joint and all of the blood that is in the joint is removed.
Study NCT02951884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
Study NCT01336608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: Inhaled corticosteroid/long acting beta-agonist
Study NCT01336608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Inhaled long acting beta-agonist
Study NCT01336608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00331773 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 3D-CRT or IMRT
Description: Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
Study NCT00331773 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated 3D-CRT or IMRT
Description: Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
Study NCT02543268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV-Batch #1
Description: Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
Study NCT02543268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV-Batch #2
Description: Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
Study NCT02543268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV-Batch #3
Description: Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
Study NCT02543268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.
Study NCT01591278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Comparison of two different pulp dressing agents
Study NCT02543268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
Study NCT02030834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
Study NCT02614885 — intervention group
Intervention type: DEVICE
Intervention: RFA
Description: Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
Study NCT00391937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Articular Surface Replacement (ASR) hip prosthesis
Description: a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
Study NCT00391937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Articular Surface Replacement (ASR) hip prosthesis
Description: a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
Study NCT04630366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-1024
Description: NST-1024
Study NCT04630366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to NST-1024
Study NCT03876158 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prometra II Programmable Pump system(Flowonix Medical)
Description: This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
Study NCT03876158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometra II Programmable Pump system(Flowonix Medical)
Description: This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
Study NCT02615873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accordion Pill™ Carbidopa/Levodopa
Description: Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
Study NCT02780921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prehabilitation
Study NCT02780921 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nutritional support
Study NCT05812222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin contact.
Description: Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
Study NCT02362594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle
Study NCT02362594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline solution administered IV on Day 1 of each 21-day cycle
Study NCT03233737 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-A
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
Study NCT03233737 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: One spray CTY-5339-A
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
Study NCT03233737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One spray CTY-5339-CB
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
Study NCT03233737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-CB
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
Study NCT03233737 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: One spray CTY-5339-P
Description: Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
Study NCT01741909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
Study NCT00665509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
Study NCT01212731 — intervention group
Intervention type: RADIATION
Intervention: Photon treatment plans
Description: 10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
Study NCT01212731 — intervention group
Intervention type: RADIATION
Intervention: Proton Treatment Plans
Description: 20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
Study NCT01212731 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurocognitive evaluation
Description: Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
Study NCT01212731 — intervention group
Intervention type: DEVICE
Intervention: Advanced MRI imaging
Description: Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
Study NCT02612415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula
Description: A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
Study NCT02612415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure
Description: CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
Study NCT00986154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban tosylate(DU-176b)
Description: edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
Study NCT00986154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin/unfractionated heparin
Description: LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment
Study NCT00986154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight heparin/unfractionated heparin
Description: LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment
Study NCT00986154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
Study NCT02278731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training program
Description: Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
Study NCT03726437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealConsent
Description: This 3-hour web-based program consists of four 45-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama (Squad), which allow for the modeling of positive behaviors and illustrate both positive and negative outcome expectations. Behaviors modeled include drinking safely (e.g., eating before drinking, pacing, and drinking water), having a game plan before going out, communicating with male sex partners, engaging in protective dating behaviors, use of resistance strategies, self-defense strategies and bystander intervention with the goal of reducing risk of being sexually assaulted.
Study NCT03726437 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stress and Mood Management
Description: This 3-hour general health promotion web-based program consists of four 45-minute modules (Stress Management, Managing Depression, Managing Anxiety, and Treatments that work) that provide a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
Study NCT03911089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: UCD Anamix Infant
Description: UCD Anamix infant with DHA and ARA is an amino acid based infant medical food containing only the essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements.
Study NCT05474261 — intervention group
Intervention type: PROCEDURE
Intervention: Valsalva maneuver
Description: Valsalva maneuver: increase intrabdominal pressure
Study NCT02744625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher doses of vasopressor therapy for a MAP of 75 mmHg
Study NCT02744625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lower doses of vasopressor therapy for a MAP of 65 mmHg
Study NCT02744625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol for light sedation
Description: Propofol for light sedation
Study NCT02744625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol for light sedation
Description: Propofol for light sedation
Study NCT01890785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Description: Single dose of a 70 mg capsule on Day 1
Study NCT01532349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for > 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
Study NCT00012194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV
Study NCT00012194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00012194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00613678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Strategy Training
Description: The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
Study NCT00613678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The health education program is based on educational materials from the Arthritis Foundation.
Study NCT04318535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 500 mg
Description: Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
Study NCT04318535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 250 mg
Description: Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.
Study NCT04318535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Griseofulvin 500 mg
Description: Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
Study NCT00646087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
Study NCT00646087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine/Saline
Description: 0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
Study NCT05061264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal wall reconstruction
Description: The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
Study NCT01197079 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Self administered anonymous survey
Study NCT03652311 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ThermoNeuroModulation TNM Device
Description: Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
Study NCT03652311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermoNeuroModulation TNM Device
Description: Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
Study NCT01173848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
Study NCT01173848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
Study NCT04044677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDSC-active
Description: 10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
Study NCT04044677 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS-sham
Description: 10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
Study NCT03421197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPC-06 400 mg QD
Description: Tepilamide Fumarate 400 mg tablet once per day
Study NCT03421197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPC-06 400 mg BID
Description: Tepilamide Fumarate tablets 400 mg twice per day
Study NCT03421197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPC-06 600 mg
Description: Tepilamide Fumarate tablets 600 mg twice per day
Study NCT03421197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
Study NCT03125668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program
Description: At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
Study NCT03125668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.